Informative neutral studies matter - Why the Targeting Inflammation with Salsalate in Cardiovascular Disease (TINSAL-CVD) trial deserves our attention

JAMA Cardiology

Volumn 1, Issue 4, 2016, Pages 423-424

  Ridker, Paul M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; FLUORODEOXYGLUCOSE F 18; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA A2 ANTIGEN; PHOSPHOLIPASE A2; TENOFOVIR DISOPROXIL; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE; SALSALATE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIRETROVIRAL THERAPY; ARTERIAL INFLAMMATION; ARTERY DISEASE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; NOTE; OUTCOME ASSESSMENT; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; VIRUS LOAD; ATTENTION; CARDIOVASCULAR DISEASE; GLUCOSE BLOOD LEVEL; INFLAMMATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATTENTION; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; SALICYLATES;

EID: 85026880117     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.0604     Document Type: Note

References (10)

1. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA. 2006;295(19):2270-2274.
2. Hauser TH, Salastekar N, Schaefer EJ, et al; Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) Study Team. Effect of targeting inflammationwith salsalate: The TINSAL-CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins [published onlineMay 25, 2016]. JAMA Cardiol. doi:10.1001/jamacardio.2016.0605.
3. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: A randomized trial. Ann Intern Med. 2010;152(6): 346-357.
4. Goldfine AB, Fonseca V, Jablonski KA, et al; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: A randomized trial. Ann Intern Med. 2013;159(1):1-12.
5. Goldfine AB, Conlin PR, Halperin F, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013;56 (4):714-723.
6. Barzilay JI, Jablonski KA, Fonseca V, et al; TINSAL-T2D Research Consortium. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes. Diabetes Care. 2014;37(4):1083-1091.
7. Goldfine AB, Buck JS, Desouza C, et al; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes-Flow-Mediated Dilation) Ancillary Study Team. Targeting inflammation using salsalate in patients with type 2 diabetes: Effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care. 2013;36(12):4132-4139.
8. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145-156.
9. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22): 2078-2087.
10. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65(13):1273-1282.